Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension

References

• AbouEzzeddine, O.F., 2017. Suppression of tumorigenicity 2 in heart failure with preserved ejection fraction. Journal of the American Heart Association, 6 (2), e004382.
   PubMed Web of Science ®Google Scholar
• Bayes-Genis, A., et al., 2013. Soluble ST2 serum concentration and renal function in heart failure. Journal of cardiac failure, 19 (11), 768–775.
   PubMed Web of Science ®Google Scholar
• Carlomagno, G., et al., 2013. Serum soluble ST2 and interleukin-33 levels in patients with pulmonary arterial hypertension. International journal of cardiology, 168 (2), 1545–1547.
   PubMed Web of Science ®Google Scholar
• Chida, A., 2014. Soluble ST2 and N-terminal pro-brain natriuretic peptide combination. Useful biomarker for predicting outcome of childhoodpulmonary arterial hypertension. Circulation journal : official journal of the Japanese Circulation Society, 78 (2), 436–442.
   PubMed Web of Science ®Google Scholar
• Daniels, L.B., et al., 2010. Association of ST2 levels with cardiac structure and function and mortality in outpatients. American heart journal, 160 (4), 721–728.
   PubMed Web of Science ®Google Scholar
• Daniels, L.B., et al., 2012. Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: Results from the BACH multinational study. European journal of heart failure, 14 (1), 22–31.
   PubMed Web of Science ®Google Scholar
• de Boer, R.A., et al., 2015. State of the art: newer biomarkers in heart failure. European journal of heart failure, 17 (6), 559–569.
   PubMed Web of Science ®Google Scholar
• de Boer, R.A., et al., 2018. Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction. JAMA cardiology, 3 (3), 215–224.
   PubMed Web of Science ®Google Scholar
• Dieplinger, B., et al., 2009. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma - The PresageTM ST2 assay. Clinica chimica acta, 409 (1–2), 33–40.
   PubMed Web of Science ®Google Scholar
• Fenster, B.E., et al., 2016. Galectin-3 levels are associated with right ventricular functional and morphologic changes in pulmonary arterial hypertension. Heart and vessels, 31 (6), 939–946.
   PubMed Web of Science ®Google Scholar
• Galiè, N., et al., 2016. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionThe Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorse. European heart journal, 37 (1), 67–119.
   PubMed Web of Science ®Google Scholar
• Geenen L.W., 2020. Growth differentiation factor-15 as candidate predictor for mortality in adults with pulmonary hypertension. Heart (British Cardiac Society), 106 (6), 467–473. Available from: https://heart.bmj.com/content/heartjnl/early/2019/09/24/heartjnl-2019-315111.full.pdf
   PubMed Web of Science ®Google Scholar
• Guth, S., et al., 2016. Pulmonary endarterectomy for the treatment of chronic thromboembolic pulmonary hypertension. Expert review of respiratory medicine, 10 (6), 673–684.
   PubMed Web of Science ®Google Scholar
• Heger, J., et al., 2010. Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes. Journal of cellular physiology, 224 (1), 120–126.
   PubMed Web of Science ®Google Scholar
• Hur, M., et al., GREAT Network. 2015. Soluble ST2 has a prognostic role in patients with suspected sepsis. Annals of laboratory medicine, 35 (6), 570–577.
   PubMed Web of Science ®Google Scholar
• Kataoka, M., et al., 2012. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circulation: cardiovascular interventions, 5 (6), 756–762.
   PubMed Web of Science ®Google Scholar
• Klok, F.A., et al., 2011. A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. Thrombosis research, 128 (1), 21–26.
   PubMed Web of Science ®Google Scholar
• Kriechbaum, S.D., et al., 2018. N-terminal pro-B-type natriuretic peptide for monitoring after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. The journal of heart and lung transplantation, 37 (5), 639–646.
   PubMed Web of Science ®Google Scholar
• Luk, K.S., et al., International Health Informatics Study (IHIS) Network. 2017. A meta-analysis of soluble suppression of tumorigenicity 2 (sST2) and clinical outcomes in pulmonary hypertension. Journal of geriatric cardiology : JGC, 14 (12), 766–771.
   PubMedGoogle Scholar
• Maron, B.A., 2016. The quest for biomarker discovery in pulmonary arterial hypertension: the right takes lessons from the left. Heart (British Cardiac Society), 102 (5), 335–336. Available from: https://heart.bmj.com/content/heartjnl/102/5/335.full.pdf
   PubMed Web of Science ®Google Scholar
• Matthews, D.T. and Hemnes, A.R., 2016. Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension. Pulmonary circulation, 6 (2), 145–154.
   PubMed Web of Science ®Google Scholar
• Mirna, M., et al., 2020. Analysis of novel cardiovascular biomarkers in patients with pulmonary hypertension (PH). Heart, lung & circulation, 29 (3), 337–344.
   PubMed Web of Science ®Google Scholar
• Mizoguchi, H., et al., 2012. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circulation: cardiovascular interventions, 5 (6), 748–755.
   PubMed Web of Science ®Google Scholar
• Mueller, T., et al., 2008. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clinical chemistry, 54 (4), 752–756.
   PubMed Web of Science ®Google Scholar
• Mueller, T. and Dieplinger, B., 2013. The Presage(®) ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert review of molecular diagnostics, 13 (1), 13–30.
   PubMed Web of Science ®Google Scholar
• Mueller, T., et al., 2015. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. Clinica chimica acta, 445, 155–160. Available from: http://www.sciencedirect.com/science/article/pii/S0009898115001771
   PubMed Web of Science ®Google Scholar
• Muller, D.W.M. and Liebetrau, C., 2016. Percutaneous treatment of chronic thromboembolic pulmonary hypertension (CTEPH). EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 12 (X), X35–X43. Available from: https://www.pcronline.com/eurointervention/X_issue/302
   PubMedGoogle Scholar
• Nickel, N., et al., 2008. Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension. American journal of respiratory and critical care medicine, 178 (5), 534–541.
   PubMed Web of Science ®Google Scholar
• Nickel, N., et al., 2011. GDF-15 is abundantly expressed in plexiform lesions in patients with pulmonary arterial hypertension and affects proliferation and apoptosis of pulmonary endothelial cells. Respiratory research, 12 (1), 62.
   PubMedGoogle Scholar
• Ogo, T., 2015. Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. Current opinion in pulmonary medicine, 2015 21, 425–431.
   Google Scholar
• Olsson, K.M., et al., 2017. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension: The initial German experience. European respiratory journal, 49 (6), 1602409.
   PubMed Web of Science ®Google Scholar
• Pascual-Figal, D.A. and Januzzi, J.L., 2015. The biology of ST2: The International ST2 Consensus Panel. The American journal of cardiology, 115 (7 Suppl), 3B–7B.
   PubMed Web of Science ®Google Scholar
• Passino, C., et al., 2015. Markers of fibrosis, inflammation, and remodeling pathways in heart failure. Clinica chimica acta, 443, 29–38.
   PubMed Web of Science ®Google Scholar
• Plácido, R., et al., 2017. Prognostic stratification in pulmonary hypertension: a multi-biomarker approach. Revista Portuguesa de cardiologia (English edition), 36 (2), 111–125.,
   Google Scholar
• Rhodes, C.J., et al., 2011. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart (British Cardiac Society), 97 (13), 1054–1060.
   PubMed Web of Science ®Google Scholar
• Sanada, S., et al., 2007. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. The Journal of clinical investigation , 117 (6), 1538–1549.
   PubMed Web of Science ®Google Scholar
• Sanchez-Mas, J., 2014. Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. European journal of clinical investigation, 44 (7), 643–651.
   PubMed Web of Science ®Google Scholar
• Shimpo, M., et al., 2004. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation, 109 (18), 2186–2190.
   PubMed Web of Science ®Google Scholar
• Simonneau, G., et al., 2017. The pathophysiology of chronic thromboembolic pulmonary hypertension. European respiratory review, 26 (143), 160112.
   PubMed Web of Science ®Google Scholar
• Tatebe, S., et al., 2016. Multiple beneficial effects of balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Circulation journal : official journal of the japanese circulation society, 80 (4), 980–988.
   PubMed Web of Science ®Google Scholar
• Weir, R.A.P., et al., 2010. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. Journal of the American College of Cardiology., 55 (3), 243–250.
   PubMed Web of Science ®Google Scholar
• Wiedenroth, C.B., et al., 2018. Balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic disease. Pulmonary circulation, 8 (1), 2045893217753122.
   Web of Science ®Google Scholar
• Wiedenroth, C.B., et al., 2018. Sequential treatment with riociguat and balloon pulmonary angioplasty for patients with inoperable chronic thromboembolic pulmonary hypertension. Pulmonary circulation, 8 (3), 2045894018783996.
   Web of Science ®Google Scholar
• Wilkens, H., et al., 2016. Chronisch thromboembolische pulmonale Hypertonie: Empfehlungen der Kölner Konsensus Konferenz 2016 TT - Chronic thromboembolic pulmonary hypertension: Recommendations of the Cologne Consensus Conference 2016. DMW - Deutsche medizinische wochenschrift, 141 (S 01), S62–S69.
   Google Scholar
• Willems, S., et al., 2013. Temporal changes of soluble ST2 after cardiovascular interventions. European journal of clinical investigation, 43 (2), 113–120.
   PubMed Web of Science ®Google Scholar
• Wollert, K.C., Kempf, T., and Wallentin, L., 2017. Growth differentiation factor 15 as a biomarker in cardiovascular disease. Clinical chemistry, 63 (1), 140–151.
   PubMed Web of Science ®Google Scholar
• Xu, J., et al., 2006. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circulation research, 98 (3), 342–350.
   PubMed Web of Science ®Google Scholar
• Zelniker, T., 2015. Novel biomarkers for risk stratification in pulmonary arterial hypertension. ERJ open research, 1 (2).
   Google Scholar